DOCS Stock Analysis — Doximity
Sector: Healthcare Software
AI Verdict
DOCS is cheap for the growth you're getting, and the physician network moat makes those earnings expectations more credible than most.
Competitive Moat
Doximity operates the largest professional network for U.S. physicians, creating high switching costs as doctors rely on its platform for secure communication and career management. Its defensibility comes from deep integration into medical workflows and a proprietary network effect among verified clinicians.
Summary
Doximity is notable for its physician-only social network, which has become an essential tool for medical professionals.
Where It Stands
DOCS trades at 18.0x next year's earnings, below the software sector median of 35x, with analysts expecting 22.4% EPS growth and a trailing PEG of 0.98 signaling the growth justifies the price.
Key Metrics
- Trailing P/E: 22.0x
- Forward P/E: 18.0x
- PEG Ratio: 0.98
- Earnings Growth: +0.2%
- Revenue Growth: +0.1%
- 52-Week High: $76.51
- 52-Week Low: $17.15
Analyst Consensus
14 Buy · 12 Hold · 2 Sell (28 analysts)
Bull Case
With forward EPS growth of 22.4% and a forward P/E of 18.0x, DOCS offers growth at a price point well below typical software peers.
Bear Case
If Doximity's P/E reverts to the sector median of 35x, the stock could see a sharp rerating, but if growth stalls, even the current 18.0x multiple could compress further, risking a double-digit percentage drop.
Catalyst to Watch
Watch for user engagement or new feature launches that could accelerate EPS growth beyond the 22.4% forecast.